CA2546843C - Composes et procedes pour accroitre la neurogenese - Google Patents

Composes et procedes pour accroitre la neurogenese Download PDF

Info

Publication number
CA2546843C
CA2546843C CA2546843A CA2546843A CA2546843C CA 2546843 C CA2546843 C CA 2546843C CA 2546843 A CA2546843 A CA 2546843A CA 2546843 A CA2546843 A CA 2546843A CA 2546843 C CA2546843 C CA 2546843C
Authority
CA
Canada
Prior art keywords
calcitonin
cells
receptor
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2546843A
Other languages
English (en)
Other versions
CA2546843A1 (fr
Inventor
Goran Bertilsson
Rikard Erlandsson
Jonas Frisen
Anders Haegestrand
Jessica Heidrich
Nina Hellstrom
Johan Haggblad
Katarina Jansson
Jarkko Kortesmaa
Per Lindquist
Hanna Lundh
Jacqueline Mcguire
Alex Mercer
Karl Nyberg
Amina Ossoinak
Cesare Patrone
Harriet Roennholm
Lilian Wikstroem
Olof Zachrisson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newron Sweden AB
Original Assignee
NeuroNova AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/718,071 external-priority patent/US20050009847A1/en
Priority claimed from US10/850,055 external-priority patent/US6969702B2/en
Application filed by NeuroNova AB filed Critical NeuroNova AB
Publication of CA2546843A1 publication Critical patent/CA2546843A1/fr
Application granted granted Critical
Publication of CA2546843C publication Critical patent/CA2546843C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés visant à activer la neurogenèse par la mise en contact de tissu neuronal avec des agents modulant la neurogenèse ; et de nouvelles méthodes de traitement de troubles neurologiques utilisant des agents modulant la neurogenèse.
CA2546843A 2003-11-20 2004-11-19 Composes et procedes pour accroitre la neurogenese Expired - Fee Related CA2546843C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/718,071 US20050009847A1 (en) 2002-11-20 2003-11-20 Compounds and methods for increasing neurogenesis
PCT/IB2003/005311 WO2004045592A2 (fr) 2002-11-20 2003-11-20 Composes et methodes permettant d'augmenter la neurogenese
US10/718,071 2003-11-20
IBPCT/IB03/05311 2003-11-20
US10/850,055 US6969702B2 (en) 2002-11-20 2004-05-19 Compounds and methods for increasing neurogenesis
US10/850,055 2004-05-19
PCT/IB2004/004451 WO2005081619A2 (fr) 2003-11-20 2004-11-19 Composes et procedes pour accroitre la neurogenese

Publications (2)

Publication Number Publication Date
CA2546843A1 CA2546843A1 (fr) 2005-09-09
CA2546843C true CA2546843C (fr) 2015-01-06

Family

ID=34915966

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2546843A Expired - Fee Related CA2546843C (fr) 2003-11-20 2004-11-19 Composes et procedes pour accroitre la neurogenese

Country Status (3)

Country Link
EP (1) EP1750752A2 (fr)
CA (1) CA2546843C (fr)
WO (1) WO2005081619A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080106950A (ko) * 2006-03-31 2008-12-09 아밀린 파마슈티칼스, 인크. 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제
JP5383498B2 (ja) * 2006-12-14 2014-01-08 ニューロノバ エービー メラノコルチン４レセプターの活性を低下させる薬剤を使用した、神経系の疾患または損傷の処置
WO2009046859A2 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
RU2010114019A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Минигастрин в качестве терапевтического средства
WO2009033809A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
WO2010024908A1 (fr) * 2008-08-26 2010-03-04 Fibrogen, Inc. Procédés de traitement de la sclérose en plaques
CN102924587B (zh) * 2011-08-11 2016-08-24 中肽生化有限公司 长效鲑鱼降钙素类似物及其制备方法和用途
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
LT2934568T (lt) 2012-12-21 2018-02-12 Sanofi Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai
WO2015086729A1 (fr) 2013-12-13 2015-06-18 Sanofi Agonistes mixtes des récepteurs glp-1/gip
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080152A1 (fr) 2013-12-13 2016-10-19 Sanofi Analogues peptidiques de l'exendine 4 non acylés
EP3080150B1 (fr) 2013-12-13 2018-08-01 Sanofi Analogues peptidiques d'exendine-4 en tant qu'agonistes du récepteur gip/glp-1 double
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104888199A (zh) * 2015-04-21 2015-09-09 徐志强 降钙素在制造治疗老年痴呆症新药物的用途
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2019170918A1 (fr) * 2018-03-09 2019-09-12 Enzypep B.V. Synthèse chimio-enzymatique de liraglutide, de semaglutide et de glp-1
CN115896029A (zh) * 2023-01-09 2023-04-04 中国人民解放军军事科学院军事医学研究院 降钙素基因相关肽在治疗帕金森病方面的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
SI1583541T1 (sl) * 2002-11-20 2011-08-31 Neuronova Ab Spojine in postopki za povečanje nevrogeneze

Also Published As

Publication number Publication date
WO2005081619A2 (fr) 2005-09-09
WO2005081619A3 (fr) 2007-04-19
EP1750752A2 (fr) 2007-02-14
CA2546843A1 (fr) 2005-09-09

Similar Documents

Publication Publication Date Title
US6969702B2 (en) Compounds and methods for increasing neurogenesis
US20090232775A1 (en) Compounds and methods for increasing neurogenesis
CA2546843C (fr) Composes et procedes pour accroitre la neurogenese
AU2003280117B2 (en) Compounds and methods for increasing neurogenesis
EP1663188B1 (fr) Traitement de maladies ou de lesions du systeme nerveux avec le fty720
US20040038888A1 (en) Functional role and potential therapeutic use of PACAP, VIP and Maxadilan in relation to adult neural stem or progenitor cells
US8435949B2 (en) Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
Bertilsson Compounds and methods for increasing neurogenesis
WO2013021196A2 (fr) Différenciation d'oligodendrocytes
WO2006136374A2 (fr) Utilisation du gip et/ou de la vitamine d3 et d'analogues correspondants pour ameliorer la differenciation de cellules souches ou progenitrices en cellules productrices d'insuline
HK1091112B (en) Compounds and methods for increasing neurogenesis
Kim Cholecystokinin Receptor Activation Promotes Pancreatic β-Cell Survival
Vaudry et al. 7th International Symposium on VIP, PACAP and Related Peptides Rouen, France September, 11–14, 2005
US20060105958A1 (en) Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20191119